BRIEF—Microbiome based drug to receive FDA review

Ferring Pharmaceuticals has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) will hold a meeting to review data supporting the biologics license application (BLA) for RBX2660, the company's microbiota-based live biotherapeutic.

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrent C. difficile infection after antibiotic treatment.
Elizabeth Garner, chief scientific officer of Ferring US, said: “The gut microbiome is a highly diverse community of microbes that plays an essential role in human health. Emerging research has shown the promise of leveraging the microbiome to address a range of conditions, including serious diseases such as recurrent C. difficile infection.”The FDA's VRBPAC meeting will take place on September 22.